Optimizing outcomes in early-stage breast cancer by tailoring the use of chemotherapy
When should we use chemotherapy in early-stage breast cancer?
• Evidence on how to guide chemotherapy treatment decisions
• A debate around patient cases proposed by a renowned panel
Prof. Eric Winer, MD, USA: The Role of the 21 Gene Recurrence Score in Decision Making for ER+ Breast Cancer
Prof. Ahmad Awada, Belgium: Optimizing outcome and benefit/risk by tailoring adjuvant chemotherapy in early stage breast cancer
Prof. Antonio Llombart, Spain: How do we manage younger patients?
Prof. Joseph Gligorov, France: Prognosis and/or Prediction - what really matters?
Prof. Ulrike Nitz, Germany: Case Report: node positive patient